This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MBIA, L-1 Identity: Volume Movers

NEW YORK (TheStreet) -- MBIA (MBI) was one of several stocks trading near $5 poised to move on above-average volume Tuesday after a mutual fund disclosed a large stake in the bond insurer.

MBIA shares rose after Fairholme Capital Management, a mutual fund headed by Bruce Berkowitz, disclosed in a regulatory filing late Monday that it owns more than 22.73 million shares of the bond insurer, or 11.1% of MBIA's outstanding stock.

Shares of MBIA jumped by 35 cents, or 5.4%, to $6.78 in the premarket session. The three-month average daily volume for MBIA is 9.91 million, according to Yahoo! Finance.

Fellow bond insurer Ambac Financial (ABK), which received a delisting warning from the New York Stock Exchange last week, was up 7.3% to 70 cents in Tuesday's premarket session.

Elsewhere, L-1 Identity Solutions (ID) slumped by 43 cents, or 5.7%, to $7.08 in Monday's late trading session after the personal identity technology company lowered its second-quarter revenue guidance to a range of $162 million to $167 million, below the Thomson Reuters average estimate for revenue of $180 million.

L-1 Identity Solutions said it will report second-quarter results on July 28, and it will also update investors on its plans to sell the company. The three-month average daily volume for L-1 Identity is 748,000.

Shares of National Bank of Greece (NBG) climbed by 8 cents, or 3.3%, to $2.54 in Tuesday's premarket session on a report that Greece, which continues to struggle with its debt load, raised roughly $2 billion in a bond auction. The three-month average daily volume for National Bank of Greece is 10.54 million.

In addition, Threshold Pharmaceuticals (THLD) jumped by 8 cents, or 7.9%, to $1.09 in the premarket session after the company announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, which selectively targets pancreatic cancer cells. The company said all combination therapy treatment groups (TH-302 plus sunitinib or sorafenib) "exhibited superior efficacy compared to the corresponding monotherapy groups."

Additionally, Threshold Pharmaceuticals said a separate presentation supports the hypothesis that TH-302 and gemcitabine "work in a complementary manner by targeting two distinct tumor compartments.". The 50-day average daily volume for Threshold is 50,000, according to the Nasdaq.

-- Written by Robert Holmes in Boston.

Check out all of Tuesday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs